Leerink group goes beyond conventional metrics to evaluate cost-effectiveness of key therapies
Leerink Partners has launched the Center for Pharmacoeconomics, which is an effort to quantify the long-term societal impact of healthcare innovations. The initiative comes as healthcare costs are under scrutiny in the U.S., while companies insist that the high prices of drugs are essential to help fund their innovation.
Leerink Partners has launched the Center for Pharmacoeconomics, which is an effort to quantify the long-term societal impact of healthcare innovations. The initiative comes as healthcare costs are under scrutiny in the U.S., while companies insist that the high prices of drugs are essential to help fund their innovation.
